Human Pathology
Volume 36, Issue 10 , Pages 1148-1151 , October 2005

Myelodysplastic/myeloproliferative disease with erythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): first description of a case

  • Simone Heiss, MD

      Affiliations

    • Institute of Pathology, Medical University of Innsbruck, 6020 Innsbruck, Austria
    • ,
  • Martin Erdel, PhD

      Affiliations

    • Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, 6020 Innsbruck, Austria
    • ,
  • Eberhard Gunsilius, MD

      Affiliations

    • Department of Hematology and Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria
    • ,
  • David Nachbaur, MD

      Affiliations

    • Department of Hematology and Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria
    • ,
  • Alexandar Tzankov, MD

      Affiliations

    • Institute of Pathology, Medical University of Innsbruck, 6020 Innsbruck, Austria
    • Corresponding Author InformationCorresponding author.

Received 16 January 2005 ,Accepted 21 July 2005.

References 

  1. Vardiman JW. Myelodysplastic/myeloproliferative diseases. In:  Jaffe ES,  Harris NL,  Stein H,  Vardiman JW editor. WHO classification of tumors—pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001;p. 47–59
  2. Mitelman F. International system for human cytogenetic nomenclature. Basel (Switzerland): Karger; 1995;
  3. http://www.ncbi.nlm.nih.gov/Omim/getmap.cgi?l600788[Accessed November 12, 2004]
  4. Mulcahy L. The erythropoietin receptor. Semin Oncol. 2001;28:19–23
  5. Sawyer ST, Penta K. Association of JAK2 and STAT5 with erythropoietin receptors. Role of receptor phosphorylation in erythropoietin signal transduction. J Biol Chem. 1996;271:32430–32437
  6. Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood. 1997;90:2535–2540
  7. http://www.ncbi.nlm.nih.gov/Omim/getmap.cgi?l605352[Accessed November 12, 2004]
  8. Pellegrini S, Dusanter-Fourt I. The structure, regulation and function of the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs). Eur J Biochem. 1997;248:615–633
  9. Devos R, Plaetinck G, Cornelis S, et al. Interleukin-5 and its receptor: a drug target for eosinophilia associated with chronic allergic disease. J Leukoc Biol. 1995;57:813–819
  10. Matsushima T, Murakami H, Tsuchiya J. Myelodysplastic syndrome with bone marrow eosinophilia: clinical and cytogenetic features. Leuk Lymphoma. 1997;15:491–497
  11. Peterson LF, Zhang DE. The 8;21 translocation in leukemogenesis. Oncogene. 2004;23:4255–4262
  12. Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol. 2002;107:101–107

☆ This study was supported by the Krebshilfe Tirol, Innsbruck, Austria.

PII: S0046-8177(05)00386-2

doi: 10.1016/j.humpath.2005.07.020

Human Pathology
Volume 36, Issue 10 , Pages 1148-1151 , October 2005

Article Tools

* Image Usage & Resolution